| P2093 | author name string | Sukhpreet Kaur | |
| | Jun Gong | |
| | Monica Mita | |
| | James Shen | |
| | John Shen | |
| | Gauri Kelekar | |
| P2860 | cites work | The blooming of the French lilac | Q22241897 |
| | Role of AMP-activated protein kinase in mechanism of metformin action | Q22241898 |
| | Metformin | Q22250907 |
| | Prospective identification of tumorigenic breast cancer cells | Q24683474 |
| | Mechanistic target of rapamycin (mTOR): a point of convergence in the action of insulin/IGF-1 and G protein-coupled receptor agonists in pancreatic cancer cells | Q26827387 |
| | Investigating metformin for cancer prevention and treatment: the end of the beginning | Q26863783 |
| | Metformin in cancer: translational challenges | Q26866388 |
| | Metformin and the risk of cancer: time-related biases in observational studies | Q26999266 |
| | Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis | Q27002540 |
| | Insulin use and cancer risk in patients with type 2 diabetes: a systematic review and meta-analysis of observational studies | Q27025720 |
| | Anti-tumor effects of metformin in animal models of hepatocellular carcinoma: a systematic review and meta-analysis | Q27306002 |
| | Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer. | Q27853104 |
| | TSC2 mediates cellular energy response to control cell growth and survival | Q27860970 |
| | Pharmacologic Therapy of Diabetes and Overall Cancer Risk and Mortality: A Meta-Analysis of 265 Studies | Q28084927 |
| | Metformin induces unique biological and molecular responses in triple negative breast cancer cells | Q28244833 |
| | Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling | Q28475546 |
| | Metformin downregulates the insulin/IGF-I signaling pathway and inhibits different uterine serous carcinoma (USC) cells proliferation and migration in p53-dependent or -independent manners | Q28486318 |
| | Metformin Causes G1-Phase Arrest via Down-Regulation of MiR-221 and Enhances TRAIL Sensitivity through DR5 Up-Regulation in Pancreatic Cancer Cells | Q28547140 |
| | Diabetes mellitus and risk of pancreatic cancer: A meta-analysis of cohort studies | Q37860602 |
| | Metformin as an antitumor agent in cancer prevention and treatment | Q37883608 |
| | Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis | Q38004476 |
| | Systematic review and meta-analysis of insulin therapy and risk of cancer. | Q38005000 |
| | Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials. | Q38033044 |
| | Thiazolidinedione use and cancer incidence in type 2 diabetes: a systematic review and meta-analysis. | Q38049935 |
| | The effects of metformin on ovarian cancer: a systematic review. | Q38156514 |
| | Metformin is associated with improved survival in endometrial cancer | Q38165601 |
| | The prognostic value of metformin for cancer patients with concurrent diabetes: a systematic review and meta-analysis | Q38181612 |
| | Metformin is associated with reduced risk of pancreatic cancer in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. | Q38212451 |
| | Effects of metformin on head and neck cancer: a systematic review | Q38337838 |
| | Metformin and breast cancer: basic knowledge in clinical context. | Q38393632 |
| | Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09). | Q38437850 |
| | Metformin synergistically sensitizes FLT3-ITD-positive acute myeloid leukemia to sorafenib by promoting mTOR-mediated apoptosis and autophagy | Q38824592 |
| | Combined Use of Metformin and Everolimus Is Synergistic in the Treatment of Breast Cancer Cells | Q38836764 |
| | Radiosensitization of metformin in pancreatic cancer cells via abrogating the G2 checkpoint and inhibiting DNA damage repair | Q38841055 |
| | PTEN, stem cells, and cancer stem cells | Q37360799 |
| | Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth | Q37365603 |
| | The epithelial-to-mesenchymal transition and cancer stem cells: a coalition against cancer therapies | Q37401193 |
| | Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: a systematic review and meta-analysis | Q37404368 |
| | Combined randomised controlled trial experience of malignancies in studies using insulin glargine | Q37418681 |
| | Metformin is a potent inhibitor of endometrial cancer cell proliferation--implications for a novel treatment strategy | Q37463664 |
| | Metformin: a potential therapeutic agent for recurrent colon cancer | Q37495759 |
| | Metformin inhibits androgen-induced IGF-IR up-regulation in prostate cancer cells by disrupting membrane-initiated androgen signaling | Q37648017 |
| | Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena | Q37715626 |
| | Metformin: taking away the candy for cancer? | Q37775372 |
| | Empowering self-renewal and differentiation: the role of mitochondria in stem cells | Q37784425 |
| | Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development | Q28831339 |
| | Metformin and reduced risk of cancer in diabetic patients | Q29616275 |
| | Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies | Q30590507 |
| | Proteomic characterization of harvested pseudopodia with differential gel electrophoresis and specific antibodies | Q31141815 |
| | A phase I study of temsirolimus and metformin in advanced solid tumours | Q33392468 |
| | Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis | Q33597162 |
| | Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. | Q33718914 |
| | Understanding the benefit of metformin use in cancer treatment | Q33864199 |
| | Profiling and targeting of cellular bioenergetics: inhibition of pancreatic cancer cell proliferation. | Q33877459 |
| | Conservative therapy with metformin plus megestrol acetate for endometrial atypical hyperplasia | Q33917333 |
| | Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state | Q33968008 |
| | Metformin and phenformin deplete tricarboxylic acid cycle and glycolytic intermediates during cell transformation and NTPs in cancer stem cells | Q33971668 |
| | Inhibition of polo-like kinase 1 (Plk1) enhances the antineoplastic activity of metformin in prostate cancer | Q34042731 |
| | The role of pre-existing diabetes mellitus on hepatocellular carcinoma occurrence and prognosis: a meta-analysis of prospective cohort studies. | Q34113485 |
| | Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders | Q34135248 |
| | Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. | Q34182185 |
| | Mechanisms by which low glucose enhances the cytotoxicity of metformin to cancer cells both in vitro and in vivo | Q34257480 |
| | Mechanism of metformin-dependent inhibition of mammalian target of rapamycin (mTOR) and Ras activity in pancreatic cancer: role of specificity protein (Sp) transcription factors | Q34283475 |
| | Insulin-like growth factors and neoplasia. | Q34330521 |
| | Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial. | Q34334262 |
| | Metformin and breast cancer risk: a meta-analysis and critical literature review | Q34357389 |
| | Diabetes, pancreatic cancer, and metformin therapy. | Q34471173 |
| | Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. | Q34506457 |
| | Very high risk of cancer in familial Peutz-Jeghers syndrome | Q34512286 |
| | Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice | Q34560435 |
| | Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo. | Q34887704 |
| | Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer | Q34984314 |
| | Use of insulin and insulin analogs and risk of cancer - systematic review and meta-analysis of observational studies. | Q35038355 |
| | Metformin use and lung cancer risk in patients with diabetes. | Q35046673 |
| | Mechanism of the mitogenic influence of hyperinsulinemia | Q35074281 |
| | Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer. | Q35084900 |
| | Synthesis and antitumor activity of an inhibitor of fatty acid synthase | Q35112277 |
| | Survival benefits of metformin for colorectal cancer patients with diabetes: a systematic review and meta-analysis | Q35125031 |
| | Survival of patients with stage IV lung cancer with diabetes treated with metformin | Q35153493 |
| | Metformin does not reduce markers of cell proliferation in esophageal tissues of patients with Barrett's esophagus. | Q35185711 |
| | Combination of Anti-Diabetic Drug Metformin and Boswellic Acid Nanoparticles: A Novel Strategy for Pancreatic Cancer Therapy | Q38841396 |
| | Metformin decreases growth of pancreatic cancer cells by decreasing reactive oxygen species: Role of NOX4. | Q38847891 |
| | The antileukemia effect of metformin in the Philadelphia chromosome-positive leukemia cell line and patient primary leukemia cell | Q38851851 |
| | Targeting stromal-induced pyruvate kinase M2 nuclear translocation impairs oxphos and prostate cancer metastatic spread. | Q38852121 |
| | Metformin inhibits the proliferation, metastasis, and cancer stem-like sphere formation in osteosarcoma MG63 cells in vitro | Q38854319 |
| | Combined therapeutic effect and molecular mechanisms of metformin and cisplatin in human lung cancer xenografts in nude mice | Q38856220 |
| | Combination of metformin and valproic acid synergistically induces cell cycle arrest and apoptosis in clear cell renal cell carcinoma | Q38867200 |
| | Dual effect of metformin on growth inhibition and oestradiol production in breast cancer cells. | Q38906009 |
| | Antidiabetic drug metformin inhibits esophageal adenocarcinoma cell proliferation in vitro and in vivo | Q38906690 |
| | Inhibition of the GTPase Rac1 mediates the antimigratory effects of metformin in prostate cancer cells. | Q38926770 |
| | Metformin potentiates the anticancer effects of cisplatin under normoxic conditions in vitro | Q38938121 |
| | Combination simvastatin and metformin induces G1-phase cell cycle arrest and Ripk1- and Ripk3-dependent necrosis in C4-2B osseous metastatic castration-resistant prostate cancer cells. | Q38938883 |
| | Effects of metformin on endometrial cancer cell growth in vivo: a preoperative prospective trial | Q38985969 |
| | Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial | Q38996447 |
| | Metformin suppresses sonic hedgehog expression in pancreatic cancer cells | Q39009084 |
| | Multidrug and toxin extrusion 1 and human organic cation transporter 1 polymorphisms in patients with castration-resistant prostate cancer receiving metformin (SAKK 08/09). | Q39031270 |
| | Metformin blocks melanoma invasion and metastasis development in AMPK/p53-dependent manner. | Q39143352 |
| | Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism. | Q39149779 |
| | Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC. | Q39340562 |
| | Metformin reduces endogenous reactive oxygen species and associated DNA damage | Q39409229 |
| | Metformin alters the expression profiles of microRNAs in human pancreatic cancer cells | Q39412212 |
| | Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers | Q39424350 |
| | Metformin inhibits renal cell carcinoma in vitro and in vivo xenograft | Q39523939 |
| | Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner | Q39707409 |
| | IGF-1 mediates PTEN suppression and enhances cell invasion and proliferation via activation of the IGF-1/PI3K/Akt signaling pathway in pancreatic cancer cells | Q39832154 |
| | The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells | Q39902046 |
| | Metformin and Rapamycin Reduce Pancreatic Cancer Growth in Obese Prediabetic Mice by Distinct MicroRNA-Regulated Mechanisms | Q39907903 |
| | In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. | Q39979957 |
| | The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. | Q40021818 |
| | Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth | Q40105523 |
| | Dual antiglioma action of metformin: cell cycle arrest and mitochondria-dependent apoptosis. | Q40143359 |
| | Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells | Q40216291 |
| | Glycolytic glioma cells with active glycogen synthase are sensitive to PTEN and inhibitors of PI3K and gluconeogenesis | Q40371829 |
| | Do endometrial cancer patients benefit from metformin intake? | Q40644828 |
| | Effect of Metformin, Rapamycin, and Their Combination on Growth and Progression of Prostate Tumors in HiMyc Mice | Q41020029 |
| | Metformin and lung cancer risk of patients with type 2 diabetes mellitus: A meta-analysis | Q41303279 |
| | Evidence for biological effects of metformin in operable breast cancer: biomarker analysis in a pre-operative window of opportunity randomized trial | Q41435904 |
| | Prediction of serious complications in patients with seemingly stable febrile neutropenia: validation of the Clinical Index of Stable Febrile Neutropenia in a prospective cohort of patients from the FINITE study | Q41563223 |
| | Metformin inhibits cell cycle progression of B-cell chronic lymphocytic leukemia cells. | Q42272463 |
| | The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia | Q42454877 |
| | Metformin Suppresses Colorectal Aberrant Crypt Foci in a Short-term Clinical Trial | Q42920181 |
| | Insulin inhibits transcription of the human gene for insulin-like growth factor-binding protein-1 | Q43430566 |
| | Prevention of pancreatic cancer induction in hamsters by metformin | Q43552285 |
| | Diabetes mellitus and risk of prostate cancer: a meta-analysis | Q44236570 |
| | Insulin-lowering effects of metformin in women with early breast cancer | Q46202863 |
| | Prospective evaluation of the molecular effects of metformin on the endometrium in women with newly diagnosed endometrial cancer: A window of opportunity study | Q46464670 |
| | Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth | Q46603046 |
| | A pilot 'window of opportunity' neoadjuvant study of metformin in localised prostate cancer. | Q46694127 |
| | Metformin does not affect cancer risk: a cohort study in the U.K. Clinical Practice Research Datalink analyzed like an intention-to-treat trial | Q48074086 |
| | The perfect arrangement | Q48092691 |
| | Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study | Q48394963 |
| | A presurgical window-of-opportunity study of metformin in obesity-driven endometrial cancer. | Q51297986 |
| | Effects of different doses of metformin treatment for 6 months on aberrant crypt foci in Chinese patients with impaired glucose tolerance. | Q51316705 |
| | Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. | Q51357213 |
| | Effect of Metformin on Breast Ductal Carcinoma In Situ Proliferation in a Randomized Presurgical Trial. | Q52924405 |
| | Association of metformin use with cancer incidence and mortality: a meta-analysis. | Q53113408 |
| | Association between metformin therapy and incidence, recurrence and mortality of prostate cancer: evidence from a meta-analysis. | Q53166209 |
| | Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer. | Q53273805 |
| | (Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II Trial. | Q53314142 |
| | Metformin Addition to Chemotherapy in Stage IV Non-Small Cell Lung Cancer: an Open Label Randomized Controlled Study. | Q53322434 |
| | Metformin synergizes 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) combination therapy through impairing intracellular ATP production and DNA repair in breast cancer stem cells. | Q53378831 |
| | Prognostic Factors in Patients Treated with 223Ra: The Role of Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT in Predicting Overall Survival. | Q53470024 |
| | Antiproliferative effect of metformin on the endometrium--a clinical trial. | Q53653820 |
| | Metformin and cancer: mounting evidence against an association. | Q54394973 |
| | Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial. | Q54583667 |
| | Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults | Q64133523 |
| | Physiological concentrations of insulin augment pancreatic cancer cell proliferation and glucose utilization by activating MAP kinase, PI3 kinase and enhancing GLUT-1 expression | Q73096655 |
| | No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis | Q84743877 |
| | [The effect of metformin on responses to chemotherapy and survival in stage IV colorectal cancer with diabetes] | Q85654982 |
| | Diabetes mellitus and the incidence and mortality of colorectal cancer: a meta-analysis of 24 cohort studies | Q87418963 |
| | Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer | Q35196533 |
| | Changes in insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: a prospective window of opportunity neoadjuvant study | Q35238162 |
| | Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models. | Q35287351 |
| | Impact of metformin use on survival in locally-advanced, inoperable non-small cell lung cancer treated with definitive chemoradiation | Q35290403 |
| | Increase in apoptosis by combination of metformin with silibinin in human colorectal cancer cells | Q35375383 |
| | Impact of metformin on clinical outcomes among men with prostate cancer: a systematic review and meta-analysis | Q35558619 |
| | Vitamin D3 potentiates the growth inhibitory effects of metformin in DU145 human prostate cancer cells mediated by AMPK/mTOR signalling pathway | Q35612112 |
| | Presurgical trial of metformin in overweight and obese patients with newly diagnosed breast cancer | Q35619082 |
| | Synergistic antitumor activity of vitamin D3 combined with metformin in human breast carcinoma MDA-MB-231 cells involves m-TOR related signaling pathways | Q35638407 |
| | Metformin potentiates rapamycin and cisplatin in gastric cancer in mice | Q35828675 |
| | Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis | Q35842470 |
| | Combined use of vitamin D3 and metformin exhibits synergistic chemopreventive effects on colorectal neoplasia in rats and mice | Q35967148 |
| | Phase II trial of metformin and paclitaxel for patients with gemcitabine-refractory advanced adenocarcinoma of the pancreas | Q35981176 |
| | Metformin-induced energy deficiency leads to the inhibition of lipogenesis in prostate cancer cells | Q36021086 |
| | Metformin: an emerging new therapeutic option for targeting cancer stem cells and metastasis | Q36026661 |
| | Combined 2-deoxy glucose and metformin improves therapeutic efficacy of sodium-iodide symporter-mediated targeted radioiodine therapy in breast cancer cells | Q36028914 |
| | Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis | Q36051510 |
| | Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance | Q36092560 |
| | Metformin combined with aspirin significantly inhibit pancreatic cancer cell growth in vitro and in vivo by suppressing anti-apoptotic proteins Mcl-1 and Bcl-2 | Q36356287 |
| | Diabetes and breast cancer risk: a meta-analysis. | Q36385281 |
| | Metformin inhibits leptin-induced growth and migration of glioblastoma cells | Q36403136 |
| | Influence of metformin intake on the risk of bladder cancer in type 2 diabetes patients | Q36410079 |
| | Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancer | Q36508067 |
| | AMP-activated protein kinase signaling in metabolic regulation | Q36528537 |
| | Metformin inhibition of mTORC1 activation, DNA synthesis and proliferation in pancreatic cancer cells: dependence on glucose concentration and role of AMPK. | Q36532994 |
| | Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth | Q36545664 |
| | Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. | Q36850905 |
| | Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model | Q37023195 |
| | Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. | Q37205539 |
| | Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner | Q37293802 |
| | Brain cancer stem cells display preferential sensitivity to Akt inhibition | Q37335643 |
| | The effect of metformin on apoptosis in a breast cancer presurgical trial. | Q37352586 |
| | Metformin inhibits pancreatic cancer cell and tumor growth and downregulates Sp transcription factors | Q37354549 |
| P433 | issue | 4 | |
| P921 | main subject | metformin | Q19484 |
| P304 | page(s) | 447-467 | |
| P577 | publication date | 2016-02-11 | |
| P1433 | published in | Targeted oncology | Q25378200 |
| P1476 | title | The expanding role of metformin in cancer: an update on antitumor mechanisms and clinical development | |
| P478 | volume | 11 | |